Jade Biosciences

Company snapshot

Jade Biosciences is a clinical-stage company developing a pipeline of potentially best-in-class therapies aimed at transforming the standard of care for patients living with autoimmune diseases.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Jade Biosciences. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Jade Biosciences.

1. Jun 5, 2026 Clinical update

   JADE201 — Phase 1

2. May 23, 2026 Clinical update

   JADE101 — Phase 2

3. May 23, 2026 Clinical update

   JADE101 — Phase 1

4. May 23, 2026 Clinical update

   JADE101 — Phase 1

5. Oct 10, 2017 Patent grant

   Ocular composition and method

View all clinical trial activity →

• What is Jade Biosciences?

  Jade Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker JBIO. Primary therapeutic focus areas include IgA Nephropathy, Rhematoid Arthritis. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 2 patent record(s) to thi

• Is Jade Biosciences publicly traded?

  Yes. Jade Biosciences is listed with ticker JBIO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Jade Biosciences develop or market?

  We link 1 drug profile(s) where Jade Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/jade-biosciences#company-drugs.

• What are the latest developments for Jade Biosciences?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Jade Biosciences focus on?

  Jade Biosciences focuses on IgA Nephropathy, Rhematoid Arthritis based on our analysis of their pipeline programs and drug development activities.